CHICAGO (EGMN) - Another phase II study has picked up a signal for cetuximab in metastatic esophageal cancer, but more data are needed to clearly define the role of epidermal growth factor receptor therapy in this setting.Therapies that target EGFR, such as the monoclonal antibody cetuximab (Erbitux), are of interest because EGFR is expressed in three-fourths of patients with esophageal cancer, and overexpression correlates with prognosis. In contrast, KRAS gene mutations occur in only about 2% of...